Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.

BACKGROUND:Novel tuberculosis vaccines should be safe, immunogenic, and effective in various population groups, including HIV-infected individuals. In this phase II multi-centre, double-blind, placebo-controlled trial, the safety and immunogenicity of the novel H1/IC31 vaccine, a fusion protein of A...

Full description

Bibliographic Details
Main Authors: Klaus Reither, Lynn Katsoulis, Trevor Beattie, Nicolene Gardiner, Nicole Lenz, Khadija Said, Elirehema Mfinanga, Christian Pohl, Katherine L Fielding, Hannah Jeffery, Benjamin M Kagina, Elisabeth J Hughes, Thomas J Scriba, Willem A Hanekom, Søren T Hoff, Peter Bang, Ingrid Kromann, Claudia Daubenberger, Peter Andersen, Gavin J Churchyard
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4260867?pdf=render

Internet

http://europepmc.org/articles/PMC4260867?pdf=render

Similar Items